Compare Abrdn Physical Platinum Shares ETF (PPLT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs TransMedics Group Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.33 (market cap $1.93B), while TransMedics Group Inc trades at $79.01 (market cap $2.81B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (962,415 versus 2,947,556). Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and TransMedics Group Inc for 24 Days on average.
| PPLT | TMDX | |
|---|---|---|
Market Cap | $1.93B | $2.81B |
Volume | 2,947,556 | 962,415 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $150.42 |
52-Week Low | $13.73 | $61.99 |
Typical Hold Time | 42 Days | 24 Days |
Enterprise Value | — | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
